MAPK8

Mitogen-activated protein kinase 8

214,420 patent compounds predicted against MAPK8, 134,445 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL157014	1.00	20/20
SCHEMBL183919	1.00	15/20
SCHEMBL183210	0.81	15/20
SCHEMBL184151	0.77	15/20
SCHEMBL183339	1.00	14/20
SCHEMBL182900	0.68	14/20
SCHEMBL183227	1.00	13/20
SCHEMBL166147	0.60	13/20
SCHEMBL182631	0.56	13/20
SCHEMBL183362	1.00	12/20
SCHEMBL184467	0.76	12/20
SCHEMBL182609	0.72	12/20
SCHEMBL182355	1.00	11/20
SCHEMBL183742	0.57	11/20
SCHEMBL161766	0.56	11/20
SCHEMBL183139	0.57	10/20
SCHEMBL183898	1.00	9/20
SCHEMBL183113	1.00	8/20
SCHEMBL182807	0.57	7/20
SCHEMBL120846	0.54	7/20

Germline variants in MAPK8 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MAPK8 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MAPK8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer	PHASE3	RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	PHASE2	COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS	PHASE2	COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	PHASE2	COMPLETED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	PHASE2	COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors	PHASE1	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	PHASE1	COMPLETED
ERK Inhibitor JSI-1187 in Advanced Solid Tumors	PHASE1	UNKNOWN
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
RASopathy Biorepository	nan	RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Glutamate Supplementation in Young Men	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAPK8 binder may also engage these)

Protein	Name	Similarity
Q8QHK8	—	1.000	Q8QHK8 →
Q90327	—	1.000	Q90327 →
P49185	—	1.000	P49185 →
O42099	—	1.000	O42099 →
P49186	—	1.000	P49186 →
P49187	—	1.000	P49187 →
Q9WTU6	—	0.999	Q9WTU6 →
MAPK9	Mitogen-activated protein kinase 9	0.997	landscape →
Q91Y86	—	0.997	Q91Y86 →
MAPK10	Mitogen-activated protein kinase 10	0.996	landscape →
P79996	—	0.995	P79996 →
Q61831	—	0.992	Q61831 →
Q9DGD9	—	0.982	Q9DGD9 →
P62205	—	0.976	P62205 →
CHEK1	Serine/threonine-protein kinase Chk1	0.976	landscape →
P92208	—	0.976	P92208 →
O35280	—	0.974	O35280 →
Q08466	—	0.974	Q08466 →
P21708	—	0.972	P21708 →
G1XJZ4	—	0.972	G1XJZ4 →
Q91ZN7	—	0.972	Q91ZN7 →
Q4WSF6	—	0.971	Q4WSF6 →
O54992	—	0.971	O54992 →
Q90ZY4	—	0.971	Q90ZY4 →
Q2TA25	—	0.971	Q2TA25 →
Q9U6D2	—	0.971	Q9U6D2 →
Q0U4L8	—	0.971	Q0U4L8 →
Q8AYC9	—	0.970	Q8AYC9 →
A1IVT7	—	0.970	A1IVT7 →
Q4PC06	—	0.970	Q4PC06 →